Primo Nutraceuticals (Primo Nutraceuticals) EV-to-EBIT : 0.00 (As of Jun. 17, 2024)

Primo Nutraceuticals EV-to-EBIT Chart

Primo Nutraceuticals Quarterly Data
	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20
EV-to-EBIT	Get a 7-Day Free Trial											-4.31	-3.92	-2.09	-2.38	-

Competitive Comparison of Primo Nutraceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Primo Nutraceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Primo Nutraceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Primo Nutraceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Primo Nutraceuticals's EV-to-EBIT falls into.

Primo Nutraceuticals EV-to-EBIT Calculation

Primo Nutraceuticals's EV-to-EBIT for today is calculated as:

Primo Nutraceuticals's current Enterprise Value is $0.00 Mil.
Primo Nutraceuticals's EBIT for the trailing twelve months (TTM) ended in Apr. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Primo Nutraceuticals  (OTCPK:BUGVF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Primo Nutraceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2020 is calculated as:

Primo Nutraceuticals's Enterprise Value for the quarter that ended in Apr. 2020 was $1.94 Mil.
Primo Nutraceuticals's EBIT for the trailing twelve months (TTM) ended in Apr. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Primo Nutraceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Primo Nutraceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Primo Nutraceuticals (Primo Nutraceuticals) Business Description